Lymphoblastoid cell lines in pharmacogenomic discovery and clinical translation

Pharmacogenomics

Volumn 13, Issue 1, 2012, Pages 55-70

  Wheeler, Heather E ^a   Dolan, M Eileen ^a  

^a SECTION OF HEMATOLOGY ONCOLOGY   (United States)

Author keywords

blockers; Acetaminophen; Chemotherapy; Cytotoxicity; Gene expression; Genome wide association studies; HapMap; Immunosuppressants; Lymphoblastoid cell lines; Pharmacogenomics; Radiation; Selective serotonin reuptake inhibitors; Statins

Indexed keywords

ASPARAGINASE; CARBOPLATIN; CISPLATIN; CYTARABINE; DAUNORUBICIN; DEOXYCYTIDINE KINASE; DEXAMETHASONE; DNA; ETOPOSIDE; FK 506 BINDING PROTEIN; FLUOROURACIL; G PROTEIN COUPLED RECEPTOR KINASE 3; GEMCITABINE; GLUTATHIONE TRANSFERASE M1; GLUTATHIONE TRANSFERASE T1; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LEUCINE ZIPPER PROTEIN; LOW DENSITY LIPOPROTEIN RECEPTOR; MITOGEN ACTIVATED PROTEIN KINASE; NERVE CELL ADHESION MOLECULE; ORGANIC CATION TRANSPORTER; ORGANIC CATION TRANSPORTER 5; PACLITAXEL; PARACETAMOL; PAROXETINE; PREDNISONE; PROTEIN BCL 2; THYMIDYLATE SYNTHASE; UNCLASSIFIED DRUG; UNINDEXED DRUG; XERODERMA PIGMENTOSUM GROUP D PROTEIN;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; BREAST CANCER; CANCER RADIOTHERAPY; CHEMOSENSITIVITY; COLORECTAL CANCER; DRUG CYTOTOXICITY; ETHNIC DIFFERENCE; FOLLOW UP; GENE EXPRESSION PROFILING; GENETIC ASSOCIATION; GENETIC LINKAGE; GENETIC VARIABILITY; GENOTYPE; HAPLOTYPE MAP; HEMATOLOGIC MALIGNANCY; HUMAN; LYMPHOBLASTOID CELL LINE; MAJOR DEPRESSION; MALIGNANT NEOPLASTIC DISEASE; ONCOGENE; OVARY CANCER; OVERALL SURVIVAL; PERSONALIZED MEDICINE; PHARMACOGENOMICS; PHENOTYPE; PREDICTION; PROGRESSION FREE SURVIVAL; QUANTITATIVE TRAIT LOCUS MAPPING; REVIEW; TREATMENT RESPONSE;

BIOMARKERS, PHARMACOLOGICAL; CELL LINE, TUMOR; DRUG DISCOVERY; GENOME-WIDE ASSOCIATION STUDY; HAPMAP PROJECT; HUMANS; INDIVIDUALIZED MEDICINE; PHARMACOGENETICS; POLYMORPHISM, GENETIC; TRANSLATIONAL MEDICAL RESEARCH;

EID: 83755207567     PISSN: 14622416     EISSN: 17448042     Source Type: Journal    
DOI: 10.2217/pgs.11.121     Document Type: Review

References (101)

1. Welsh M, Mangravite L, Medina MW et al. Pharmacogenomic discovery using cell-based models. Pharmacol. Rev. 61(4), 413-429 (2009).
2. Gamazon ER, Zhang W, Konkashbaev A et al. SCAN: SNP and copy number annotation. Bioinformatics 26(2), 259-262 (2010).
3. Zhou SF, Liu JP, Chowbay B. Polymorphism of human cytochrome P450 enzymes and its clinical impact. Drug Metab. Rev. 41(2), 89-295 (2009).
4. van Baarsen LG, Vosslamber S, Tijssen M et al. Pharmacogenomics of interferon-beta therapy in multiple sclerosis: baseline IFN signature determines pharmacological differences between patients. PLoS ONE 3(4), e1927 (2008).
5. Wertz IE, Kusam S, Lam C et al. Sensitivity to antitubulin chemotherapeutics is regulated by MCL1 and FBW7. Nature 471(7336), 110-114 (2011).
6. Choy E, Yelensky R, Bonakdar S et al. Genetic analysis of human traits in vitro: drug response and gene expression in lymphoblastoid cell lines. PLoS Genet. 4(11), e1000287 (2008).
7. Stark AL, Zhang W, Mi S et al. Heritable and non-genetic factors as variables of pharmacologic phenotypes in lymphoblastoid cell lines. Pharmacogenomics J. 10(6), 505-512 (2010).
8. Liu MT, Chen YR, Chen SC et al. Epstein-Barr virus latent membrane protein 1 induces micronucleus formation, represses DNA repair and enhances sensitivity to DNA-damaging agents in human epithelial cells. Oncogene 23(14), 2531-2539 (2004).
9. Caliskan M, Cusanovich DA, Ober C, Gilad Y. The effects of EBV transformation on gene expression levels and methylation profiles. Hum. Mol. Genet. 20(8), 1643-1652 (2011).
10. Bullaughey K, Chavarria CI, Coop G, Gilad Y. Expression quantitative trait loci detected in cell lines are often present in primary tissues. Hum. Mol. Genet. 18(22), 4296-4303 (2009).
11. Ding J, Gudjonsson JE, Liang L et al. Gene expression in skin and lymphoblastoid cells: refined statistical method reveals extensive overlap in cis-eQTL signals. Am. J. Hum. Genet. 87(6), 779-789 (2010).
12. Schadt EE, Molony C, Chudin E et al. Mapping the genetic architecture of gene expression in human liver. PLoS Biol. 6(5), e107 (2008).
13. Dausset J, Cann H, Cohen D, Lathrop M, Lalouel JM, White R. Centre d'Etude du Polymorphisme Humain (CEPH): collaborative genetic mapping of the human genome. Genomics 6(3), 575-577 (1990). (Pubitemid 20168693)
14. Thorisson GA, Stein LD. The SNP Consortium website: past, present and future. Nucleic Acids Res. 31(1), 124-127 (2003). (Pubitemid 36150350)
15. Morley M, Molony CM, Weber TM et al. Genetic analysis of genome-wide variation in human gene expression. Nature 430(7001), 743-747 (2004). (Pubitemid 39071339)
16. Burdick JT, Chen WM, Abecasis GR, Cheung VG. In silico method for inferring genotypes in pedigrees. Nat. Genet. 38(9), 1002-1004 (2006). (Pubitemid 44325924)
17. Dolan ME, Newbold KG, Nagasubramanian R et al. Heritability and linkage analysis of sensitivity to cisplatin-induced cytotoxicity. Cancer Res. 64(12), 4353-4356 (2004). (Pubitemid 38802443)
18. Watters JW, Kraja A, Meucci MA, Province MA, McLeod HL. Genome-wide discovery of loci influencing chemotherapy cytotoxicity. Proc. Natl Acad. Sci. USA 101(32), 11809-11814 (2004). (Pubitemid 39095376)
19. Altshuler D, Brooks LD, Chakravarti A, Collins FS, Daly MJ, Donnelly P. A haplotype map of the human genome. Nature 437(7063), 1299-1320 (2005).
20. Altshuler DM, Gibbs RA, Peltonen L et al. Integrating common and rare genetic variation in diverse human populations. Nature 467(7311), 52-58 (2010).
21. Frazer KA, Ballinger DG, Cox DR et al. A second generation human haplotype map of over 3.1 million SNPs. Nature 449(7164), 851-861 (2007). (Pubitemid 47598626)
22. Thorisson GA, Smith AV, Krishnan L, Stein LD. The International HapMap Project Web site. Genome Res. 15(11), 1592-1593 (2005). (Pubitemid 41545013)
23. The 1000 Genomes Project Consortium. A map of human genome variation from population-scale sequencing. Nature 467(7319), 1061-1073 (2010).
24. O'Donnell PH, Dolan ME. Cancer pharmacoethnicity: ethnic differences in susceptibility to the effects of chemotherapy. Clin. Cancer Res. 15(15), 4806-4814 (2009).
25. Calvo E, Baselga J. Ethnic differences in response to epidermal growth factor receptor tyrosine kinase inhibitors. J. Clin. Oncol. 24(14), 2158-2163 (2006). (Pubitemid 46630688)
26. Rotimi CN, Jorde LB. Ancestry and disease in the age of genomic medicine. N. Engl. J. Med. 363(16), 1551-1558 (2010).
27. Need AC, Goldstein DB. Next generation disparities in human genomics: concerns and remedies. Trends Genet. 25(11), 489-494 (2009).
28. Wheeler HE, Gorsic LK, Welsh M et al. Genome-wide local ancestry approach identifies genes and variants associated with chemotherapeutic susceptibility in African-Americans. PLoS ONE 6(7), e21920 (2011).
29. Dumitrescu L, Carty CL, Taylor K et al. Genetic determinants of lipid traits in diverse populations from the Population Architecture using Genomics and Epidemiology (PAGE) study. PLoS Genet. 7(6), e1002138 (2011).
30. Peters EJ, Kraja AT, Lin SJ et al. Association of thymidylate synthase variants with 5 fluorouracil cytotoxicity. Pharmacogenet. Genomics 19(5), 399-401 (2009).
31. Pinedo HM, Peters GF. Fluorouracil: biochemistry and pharmacology. J. Clin. Oncol. 6(10), 1653-1664 (1988).
32. Gamazon ER, Huang RS, Cox NJ, Dolan ME. Chemotherapeutic drug susceptibility associated SNPs are enriched in expression quantitative trait loci. Proc. Natl Acad. Sci. USA 107(20), 9287-9292 (2010).
33. Matsson P, Yee SW, Markova S et al. Discovery of regulatory elements in human ATP-binding cassette transporters through expression quantitative trait mapping. Pharmacogenomics J. doi:10.1038/tpj.2011.8 (2011) (Epub ahead of print).
34. Huang RS, Duan S, Bleibel WK et al. A genome-wide approach to identify genetic variants that contribute to etoposide-induced cytotoxicity. Proc. Natl Acad. Sci. USA 104(23), 9758-9763 (2007). (Pubitemid 47175340)
35. Hartford CM, Duan S, Delaney SM et al. Population-specific genetic variants important in susceptibility to cytarabine arabinoside cytotoxicity. Blood 113(10), 2145-2153 (2009).
36. Yin G, Zheng Q, Yan C, Berk BC. GIT1 is a scaffold for ERK1/2 activation in focal adhesions. J. Biol. Chem. 280(30), 27705-27712 (2005). (Pubitemid 41076884)
37. Lu Z, Xu S. ERK1/2 MAP kinases in cell survival and apoptosis. IUBMB Life 58(11), 621-631 (2006). (Pubitemid 44691463)
38. Shaw GC, Cope JJ, Li L et al. Mitoferrin is essential for erythroid iron assimilation. Nature 440(7080), 96-100 (2006). (Pubitemid 43336274)
39. Leardi A, Caraglia M, Selleri C et al. Desferioxamine increases iron depletion and apoptosis induced by ara C of human myeloid leukaemic cells. Br. J. Haematol. 102(3), 746-752 (1998). (Pubitemid 28387058)
40. Lamba JK, Crews K, Pounds S et al. Pharmacogenetics of deoxycytidine kinase: identification and characterization of novel genetic variants. J. Pharmacol. Exp. Ther. 323(3), 935-945 (2007). (Pubitemid 350146062)
41. Gamazon ER, Duan S, Zhang W et al. PACdb: A database for cell-based pharmacogenomics. Pharmacogenet. Genomics 20(4), 269-273 (2010).
42. Li L, Fridley BL, Kalari K et al. Gemcitabine and arabinosylcytosin pharmacogenomics: genome-wide association and drug response biomarkers. PLoS ONE 4(11), e7765 (2009).
43. Shin BK, Wang H, Yim AM et al. Global profiling of the cell surface proteome of cancer cells uncovers an abundance of proteins with chaperone function. J. Biol. Chem. 278(9), 7607-7616 (2003). (Pubitemid 36800769)
44. Trenkle T, McClelland M, Adlkofer K, Welsh J. Major transcript variants of VAV3, a new member of the VAV family of guanine nucleotide exchange factors. Gene 245(1), 139-149 (2000). (Pubitemid 30125373)
45. Kalari KR, Hebbring SJ, Chai HS et al. Copy number variation and cytidine analogue cytotoxicity: A genome-wide association approach. BMC Genomics 11, 357 (2010).
46. O'Donnell PH, Gamazon E, Zhang W et al. Population differences in platinum toxicity as a means to identify novel genetic susceptibility variants. Pharmacogenet. Genomics 20(5), 327-337 (2010).
47. Millward MJ, Boyer MJ, Lehnert M et al. Docetaxel and carboplatin is an active regimen in advanced non-small-cell lung cancer: A Phase II study in Caucasian and Asian patients. Ann. Oncol. 14(3), 449-454 (2003). (Pubitemid 36367424)
48. Wu B, Droge P, Davey CA. Site selectivity of platinum anticancer therapeutics. Nat. Chem. Biol. 4(2), 110-112 (2008).
49. Wang D, Lippard SJ. Cisplatin-induced post-translational modification of histones H3 and H4. J. Biol. Chem. 279(20), 20622-20625 (2004). (Pubitemid 38656456)
50. Wheeler HE, Gamazon ER, Stark AL et al. Genome-wide meta-analysis identifies variants associated with platinating agent susceptibility across populations. Pharmacogenomics J. doi:10.1038/tpj.2011.38. (2011) (Epub ahead of print).
51. Eliopoulos AG, Kerr DJ, Herod J et al. The control of apoptosis and drug resistance in ovarian cancer: influence of p53 and Bcl 2. Oncogene 11(7), 1217-1228 (1995).
52. Marsh S, McLeod H, Dolan E et al. Platinum pathway. Pharmacogenet. Genomics 19(7), 563-564 (2009).
53. Rabik CA, Dolan ME. Molecular mechanisms of resistance and toxicity associated with platinating agents. Cancer Treat. Rev. 33(1), 9-23 (2007). (Pubitemid 46137553)
54. Shukla SJ, Duan S, Badner JA, Wu X, Dolan ME. Susceptibility loci involved in cisplatin-induced cytotoxicity and apoptosis. Pharmacogenet. Genomics 18(3), 253-262 (2008). (Pubitemid 351323240)
55. Wen Y, Gorsic LK, Wheeler HE, Ziliak DM, Huang SR, Dolan EM. Chemotherapeutic-induced apoptosis: A phenotype for pharmacogenomics studies. Pharmacogenet. Genomics 21(8), 476-488 (2011).
56. French D, Yang W, Cheng C et al. Acquired variation outweighs inherited variation in whole genome analysis of methotrexate polyglutamate accumulation in leukemia. Blood 113(19), 4512-4520 (2009).
57. West CM, Elliott RM, Burnet NG. The genomics revolution and radiotherapy. Clin. Oncol. (R. Coll. Radiol.) 19(6), 470-480 (2007). (Pubitemid 46995613)
58. Smirnov DA, Morley M, Shin E, Spielman RS, Cheung VG. Genetic analysis of radiation-induced changes in human gene expression. Nature 459(7246), 587-591 (2009).
59. Wyrobek AJ, Manohar CF, Krishnan VV et al. Low dose radiation response curves, networks and pathways in human lymphoblastoid cells exposed from 1 to 10cGy of acute gamma radiation. Mutat. Res. 722(2), 119-130 (2011).
60. Niu N, Qin Y, Fridley BL et al. Radiation pharmacogenomics: A genome-wide association approach to identify radiation response biomarkers using human lymphoblastoid cell lines. Genome Res. 20(11), 1482-1492 (2010).
61. LaRosa JC, He J, Vupputuri S. Effect of statins on risk of coronary disease: A meta-analysis of randomized controlled trials. JAMA 282(24), 2340-2346 (1999). (Pubitemid 30013066)
62. Simon JA, Lin F, Hulley SB et al. Phenotypic predictors of response to simvastatin therapy among African-Americans and Caucasians: the Cholesterol and Pharmacogenetics (CAP) Study. Am. J. Cardiol. 97(6), 843-850 (2006).
63. Krauss RM, Mangravite LM, Smith JD et al. Variation in the 3 hydroxyl 3 methylglutaryl coenzyme a reductase gene is associated with racial differences in low-density lipoprotein cholesterol response to simvastatin treatment. Circulation 117(12), 1537-1544 (2008). (Pubitemid 351440642)
64. Medina MW, Gao F, Ruan W, Rotter JI, Krauss RM. Alternative splicing of 3 hydroxy 3 methylglutaryl coenzyme A reductase is associated with plasma low-density lipoprotein cholesterol response to simvastatin. Circulation 118(4), 355-362 (2008).
65. Mangravite LM, Medina MW, Cui J et al. Combined influence of LDLR and HMGCR sequence variation on lipid-lowering response to simvastatin. Arterioscler. Thromb. Vasc. Biol. 30(7), 1485-1492 (2010).
66. Souery D, Oswald P, Massat I et al. Clinical factors associated with treatment resistance in major depressive disorder: results from a European multicenter study. J. Clin. Psychiatry 68(7), 1062-1070 (2007). (Pubitemid 47340327)
67. Kirchheiner J, Nickchen K, Bauer M et al. Pharmacogenetics of antidepressants and antipsychotics: the contribution of allelic variations to the phenotype of drug response. Mol. Psychiatry 9(5), 442-473 (2004). (Pubitemid 38903502)
68. Morag A, Pasmanik-Chor M, Oron-Karni V, Rehavi M, Stingl JC, Gurwitz D. Genome-wide expression profiling of human lymphoblastoid cell lines identifies CHL1 as a putative SSRI antidepressant response biomarker. Pharmacogenomics 12(2), 171-184 (2011).
69. Montag-Sallaz M, Baarke A, Montag D. Aberrant neuronal connectivity in CHL1-deficient mice is associated with altered information processing-related immediate early gene expression. J. Neurobiol. 57(1), 67-80 (2003). (Pubitemid 37087787)
70. Chen QY, Chen Q, Feng GY et al. Case-control association study of the close homologue of L1 (CHL1) gene and schizophrenia in the Chinese population. Schizophr. Res. 73(2-3), 269-274 (2005). (Pubitemid 40093889)
71. Sakurai K, Migita O, Toru M, Arinami T. An association between a missense polymorphism in the close homologue of L1 (CHL1, CALL) gene and schizophrenia. Mol. Psychiatry 7(4), 412-415 (2002). (Pubitemid 34499363)
72. Wu TY, Fridley BL, Jenkins GD, Batzler A, Wang L, Weinshilboum RM. Mycophenolic acid response biomarkers: A cell line model system-based genome-wide screen. Int. Immunopharmacol. 11(8), 1057-1064 (2011).
73. Niu N, Manickam V, Kalari KR et al. Human glucocorticoid receptor alpha gene (NR3C1) pharmacogenomics: gene resequencing and functional genomics. J. Clin. Endocrinol. Metab. 94(8), 3072-3084 (2009).
74. Moyer AM, Fridley BL, Jenkins GD et al. Acetaminophen-NAPQI hepatotoxicity: A cell line model system genome-wide association study. Toxicol. Sci. 120(1), 33-41 (2011).
75. Penela P, Murga C, Ribas C, Tutor AS, Peregrin S, Mayor F Jr. Mechanisms of regulation of G protein-coupled receptor kinases (GRKs) and cardiovascular disease. Cardiovasc. Res. 69(1), 46-56 (2006). (Pubitemid 41814810)
76. Lobmeyer MT, Wang L, Zineh I et al. Polymorphisms in genes coding for GRK2 and GRK5 and response differences in antihypertensive-treated patients. Pharmacogenet. Genomics 21(1), 42-49 (2011).
77. Li L, Fridley B, Kalari K et al. Gemcitabine and cytosine arabinoside cytotoxicity: association with lymphoblastoid cell expression. Cancer Res. 68(17), 7050-7058 (2008).
78. Pei H, Li L, Fridley BL et al. FKBP51 affects cancer cell response to chemotherapy by negatively regulating Akt. Cancer Cell 16(3), 259-266 (2009).
79. Mitra AK, Crews K, Pounds S et al. Impact of genetic variation in FKBP5 on clinical response in pediatric acute myeloid leukemia patients: A pilot study. Leukemia 25(8), 1354-1356 (2011).
80. Chen SH, Yang W, Fan Y et al. A genome-wide approach identifies that the aspartate metabolism pathway contributes to asparaginase sensitivity. Leukemia 25(1), 66-74 (2011).
81. Ziliak D, O'Donnell P H, Im HK et al. Germline polymorphisms discovered via a cell-based, genome-wide approach predict platinum response in head and neck cancers. Transl. Res. 157(5), 265-272 (2011).
82. Huang RS, Johnatty SE, Gamazon ER et al. Platinum sensitivity-related germline polymorphism discovered via a cell-based approach and analysis of its association with outcome in ovarian cancer patients. Clin. Cancer Res. 17(16), 1-11 (2011).
83. Tan XL, Moyer AM, Fridley BL et al. Genetic variation predicting cisplatin cytotoxicity associated with overall survival in lung cancer patients receiving platinum-based chemotherapy. Clin. Cancer Res. 17(17), 5801-5811 (2011).
84. Ingle JN, Schaid DJ, Goss PE et al. Genome-wide associations and functional genomic studies of musculoskeletal adverse events in women receiving aromatase inhibitors. J. Clin. Oncol. 28(31), 4674-4682 (2010).
85. Matys V, Fricke E, Geffers R et al. TRANSFAC: transcriptional regulation, from patterns to profiles. Nucleic Acids Res. 31(1), 374-378 (2003). (Pubitemid 36150406)
86. Kaiser J. DNA sequencing. A plan to capture human diversity in 1000 genomes. Science 319(5862), 395 (2008). (Pubitemid 351160548)
87. Li B, Leal SM. Methods for detecting associations with rare variants for common diseases: application to analysis of sequence data. Am. J. Hum. Genet. 83(3), 311-321 (2008).
88. Liu JZ, McRae AF, Nyholt DR et al. A versatile gene-based test for genome-wide association studies. Am. J. Hum. Genet. 87(1), 139-145 (2010).
89. Tatonetti NP, Dudley JT, Sagreiya H, Butte AJ, Altman RB. An integrative method for scoring candidate genes from association studies: application to warfarin dosing. BMC Bioinformatics 11(Suppl. 9), S9 (2010).
90. Zhu X, Feng T, Li Y, Lu Q, Elston RC. Detecting rare variants for complex traits using family and unrelated data. Genet. Epidemiol. 34(2), 171-187 (2010).
91. Gamazon ER, Im HK, Duan S et al. Exprtarget: an integrative approach to predicting human microRNA targets. PLoS ONE 5(10), e13534 (2010).
92. Wang L, Oberg AL, Asmann YW et al. Genome-wide transcriptional profiling reveals microRNA-correlated genes and biological processes in human lymphoblastoid cell lines. PLoS ONE 4(6), e5878 (2009).
93. Bell JT, Pai AA, Pickrell JK et al. DNA methylation patterns associate with genetic and gene expression variation in HapMap cell lines. Genome Biol. 12(1), R10 (2011).
94. Sugawara H, Iwamoto K, Bundo M, Ueda J, Ishigooka J, Kato T. Comprehensive DNA methylation analysis of human peripheral blood leukocytes and lymphoblastoid cell lines. Epigenetics 6(4), 508-515 (2011).
95. Baer-Dubowska W, Majchrzak-Celinska A, Cichocki M. Pharmocoepigenetics: A new approach to predicting individual drug responses and targeting new drugs. Pharmacol. Rep. 63(2), 293-304 (2011).
96. Mishra PJ, Banerjee D, Bertino JR. MiRSNPs or MiR-polymorphisms, new players in microRNA mediated regulation of the cell: introducing microRNA pharmacogenomics. Cell Cycle 7(7), 853-858 (2008). (Pubitemid 351573776)
97. Zhang W, Huang RS, Dolan ME. Integrating epigenomics into pharmacogenomic studies. Pharmgenomics Pers. Med. 2008(1), 7-14 (2008).
98. Ciaccio MF, Wagner JP, Chuu CP, Lauffenburger DA, Jones RB. Systems analysis of EGF receptor signaling dynamics with microwestern arrays. Nat. Methods 7(2), 148-155 (2010).
99. Nica AC, Montgomery SB, Dimas AS et al. Candidate causal regulatory effects by integration of expression QTLs with complex trait genetic associations. PLoS Genet. 6(4), e1000895 (2010).
100. Nicolae DL, Gamazon E, Zhang W, Duan S, Dolan ME, Cox NJ. Trait-associated SNPs are more likely to be eQTLs: annotation to enhance discovery from GWAS. PLoS Genet. 6(4), e1000888 (2010).
101. Relling MV, Gardner EE, Sandborn WJ et al. Clinical Pharmacogenetics Implementation Consortium guidelines for thiopurine methyltransferase genotype and thiopurine dosing. Clin. Pharmacol. Ther. 89(3), 387-391 (2011).